Patent Yard Sign in
Expired European patentEurope

Recombinant adenoviruses coding for glial-derived neurotrophic factor (gdnf)

EP 0752004 B1 · Applicant: Aventis Pharma S.A.

EPO PDF

Overview

The published document from the EPO: abstract, claims, description and drawings. Open it full size

Read the whole patent

Listed from its EPO record in Patent Yard's archive of European patents past their term. Its claims, description and drawings are in the EPO PDF and on Google Patents, and the Claude kit works from them.

Google PatentsEPO PDF

Why it's free to use

  • Filed March 23, 1995 and granted August 9, 2006. A European patent lasts at most 20 years from filing, so its term ended March 23, 2015.
  • A supplementary protection certificate, which can extend a medicine or crop-protection patent, adds at most five and a half years, so even that would have ended by September 23, 2020.
  • We check European rights only. A US or other national patent in its family could still be in force: check its family on Espacenet or Google Patents.
FiledMarch 23, 1995
PublishedJanuary 8, 1997
GrantedAugust 9, 2006
Term endedMarch 23, 2015
Application numberEP 95914402
Classification (CPC)A61P25/00 +2 more

Timeline

Timeline From EPO dates

1996199820002002200420062008201020122014Application filedMarch 23, 1995PublishedJan 8, 1997Patent grantedAug 9, 2006Term endedMarch 23, 2015

Sources & verification

Official EPO records

Full published documentClaims, description and drawings as a PDF.EPOEuropean Patent RegisterProcedure, status, file inspection and legal events.EPOLinked open EP data recordThe bibliographic record this page is built from.EPO

Cross-check elsewhere

Google PatentsFull text, worldwide family, citing patents and legal events.patents.google.comEspacenetNational family members and their legal status.European Patent Office

Everything on this page comes from the EPO record linked above. EPO data used under CC BY 4.0.